All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
FDA grants orphan drug designation to iadademstat
On February 11, 2021, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to iadademstat for the treatment of acute myeloid leukemia (AML).1
Iadademstat
Iadademstat is an orally available, investigational, lysine-specific histone demethylase 1 (LSD1) inhibitor, which binds covalently to the flavin adenine dinucleotide (FAD) within the active site of LSD1.2
LSD1 is a chromatin remodeling enzyme responsible for the epigenetic regulation of a number of transcription factors involved in leukemia progression. Inhibition of LSD1 has demonstrated a potent differentiating effect in hematological cancers.1
Clinical status
The first-in-human phase I/IIa study investigating iadademstat in patients with relapsed or refractory AML showed that iadademstat monotherapy has a good safety profile and both clinical and biological activity.3 Data from this study provided the grounds for the ongoing phase II ALICE study, evaluating iadademstat in combination with azacitidine in newly diagnosed, elderly patients with AML.
Safety and efficacy data from the phase IIa ALICE trial were presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting the safety and tolerability of the regimen, as well as its robust clinical efficacy in elderly patients with AML who were ineligible for intensive chemotherapy. The following outcomes were reported for a total of 13 evaluable patients as per protocol (18 enrolled patients) 4:
- Overall response rate (ORR) as per protocol: 85%
- ORR as per intention to treat: 61%
- Complete remission (CR)/CR with incomplete hematological recovery (CRi) rate: 64%
- Partial remission rate: 36%
- Mean time to response: 34 days
- Proportion of CR/CRi lasting > 6 months: 86%
- Median duration of response: 308 days
The typical response rate for patients treated with azacitidine monotherapy in this setting is approximately 27%.4 Therefore, the data indicate a synergistic interaction between azacitidine and iadademstat. Recruitment for the ALICE trial has now resumed after disruption caused by the COVID-19 pandemic, and further results are anticipated.5
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What barriers do you encounter when conducting multiple MRD tests during treatment?